Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
216.66
+1.08 (0.50%)
At close: Jan 21, 2026, 4:00 PM EST
216.66
0.00 (0.00%)
After-hours: Jan 21, 2026, 4:10 PM EST
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M EUR
Revenue Growth
+97.46%
P/S Ratio
17.12
Revenue / Employee
635,740 EUR
Employees
1,017
Market Cap
13.30B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.29B |
| Moderna | 2.23B |
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 966.96M |
| Madrigal Pharmaceuticals | 740.64M |
| BridgeBio Pharma | 353.78M |
ASND News
- 9 days ago - Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 12 days ago - Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript - Seeking Alpha
- 13 days ago - Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - GlobeNewsWire
- 16 days ago - Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Here's My Prediction For Who Could Acquire Ascendis Pharma - Seeking Alpha
- 5 weeks ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 5 weeks ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha